Stereotaxis (NYSE:STXS) announced today that it appointed two new vice presidents who both have extensive industry experience.
Frank Van Hyfte will join the St. Louis–based surgical robotics company as VP of Europe, the Middle East and Africa, and Tim Glynn will join as VP of market development.
Van Hyfte previously spent more than 15 years at Intuitive Surgical, rising from clinical specialist to director of direct and indirect markets in Europe, the Middle East, India and Africa. He also served in senior commercial leadership roles at Exact Imaging, EDAP TMS and eCential Robotics.
Glynn was most recently VP of business and market development at Acutus Medical. There, he established commercial beachheads in Europe and the U.S. to manage product marketing, physician relationships and business partnerships, Stereotaxis said in a news release. Glynn also served in senior marketing roles at Volcano Corporation.
“We see in Stereotaxis the opportunity to build a preeminent robotic surgery company that positively transforms electrophysiology specifically and endovascular surgery more broadly,” Van Hyfte and Glynn said in a joint statement. “We join Stereotaxis at a fitting time as it establishes the product ecosystem that can allow for substantial commercial growth. We look forward to working together with the existing Stereotaxis team in building a highly impactful commercial organization.”
Van Hyfte and Glynn join Michael Tropea, VP of North America, and Casey Payne, VP of Asia Pacific, on Stereotaxis’ existing commercial leadership team.
“Stereotaxis has been energetically advancing a robust innovation pipeline that enables significant adoption of robotics across electrophysiology and endovascular surgery,” Stereotaxis Chair and CEO David Fischel said. “In preparation for these product launches, we are assembling the right commercial leadership and establishing the commercial foundations for significant growth. We are excited to welcome Frank and Tim to the Stereotaxis team and look forward to their contributions as leaders in our efforts to pioneer endovascular robotics.”